IceCure Medical (NasdaqCM:ICCM) Q3 2025 Earnings Call November 19, 2025 10:00 AM ET Speaker2Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management's discussion, there'll be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polyviou. Please go ahead.Speaker0Thank you, Ella, and welcome to IceCure Medical's conference call to review the finan ...

Core Viewpoint - IceCure Medical Ltd. is advancing minimally-invasive cryoablation technology for tumor treatment, particularly focusing on breast cancer, as demonstrated at the European Conference on Interventional Oncology 2025 [1][2] Company Overview - IceCure Medical develops and markets cryoablation therapy systems that utilize liquid nitrogen to destroy tumors, with a primary focus on breast, kidney, bone, and lung cancers [9] - The ProSense® system is highlighted as a leading cryoablation system for early-stage breast cancer tumors, reflecting its commercial adoption in Europe and other global markets [2][9] Conference Participation - IceCure Medical participated in ECIO 2025, where breast cancer cryoablation was a major focus, featuring ProSense® in seven key events [1][2] - The conference included scientific sessions and presentations showcasing the effectiveness of ProSense® in treating breast cancer [3][4] Clinical Data and Findings - A poster presentation indicated that cryoablation combined with hormonal therapy resulted in a 94% tumor size reduction, outperforming hormonal therapy or cryoablation alone [3] - In a study comparing cryoablation to other thermal ablation techniques, cryoablation achieved a 94% efficacy rate with no complications, and 95% of patients preferred thermal ablation over traditional surgery [5] - The mean overall progression-free survival for patients treated with cryoablation was reported at 2.9 years [5] Training and Expert Exchange - Hands-on training sessions for ProSense® were well attended, indicating strong interest and engagement from medical professionals [4] - Expert discussions on breast cancer cryoablation were conducted, highlighting the perspectives of both breast surgeons and interventional oncologists [4]